Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy

Meng Li,Xueyu Zhao,Chuanfei Yu,Lan Wang

DOI: https://doi.org/10.1007/s11095-023-03649-z

IF: 4.58

2024-02-18

Pharmaceutical Research

Abstract:Antibody-drug conjugates (ADCs) comprise an antibody, linker, and drug, which direct their highly potent small molecule drugs to target tumor cells via specific binding between the antibody and surface antigens. The antibody, linker, and drug should be properly designed or selected to achieve the desired efficacy while minimizing off-target toxicity. With a unique and complex structure, there is inherent heterogeneity introduced by product-related variations and the manufacturing process. Here this review primarily covers recent key advances in ADC history, clinical development status, molecule design, manufacturing processes, and quality control. The manufacturing process, especially the conjugation process, should be carefully developed, characterized, validated, and controlled throughout its lifecycle. Quality control is another key element to ensure product quality and patient safety. A patient-centric strategy has been well recognized and adopted by the pharmaceutical industry for therapeutic proteins, and has been successfully implemented for ADCs as well, to ensure that ADC products maintain their quality until the end of their shelf life. Deep product understanding and process knowledge defines attribute testing strategies (ATS). Quality by design (QbD) is a powerful approach for process and product development, and for defining an overall control strategy. Finally, we summarize the current challenges on ADC development and provide some perspectives that may help to give related directions and trigger more cross-functional research to surmount those challenges.

pharmacology & pharmacy,chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper attempts to address the key challenges in the manufacturing process of Antibody-Drug Conjugates (ADCs) and how to ensure product quality and patient safety. Specifically, the paper covers the following aspects:

1. **History and Technological Accumulation**: Reviews the development history of ADCs, from the earliest theoretical proposals to the rapid advancements in recent years, particularly the breakthrough achievements of third-generation ADCs.

2. **Molecular Design**: Discusses the design principles of the components of ADCs (antibody, linker, drug), including how to select and optimize these components to enhance efficacy and reduce off-target toxicity.

3. **Manufacturing Process**: Provides a detailed introduction to the manufacturing process of ADCs, including the production of monoclonal antibodies, preparation of linkers and small molecule drugs, conjugation reactions, and the preparation of the final product. It particularly emphasizes the advantages and disadvantages of non-site-specific and site-specific conjugation techniques.

4. **Quality Control**: Explores the quality control strategies for ADCs, including the identification of critical quality attributes (CQA), control of critical process parameters (CPP), and the development of an overall control strategy. It proposes a risk assessment-based Design of Experiments (DoE) approach to ensure the reliability and reproducibility of the production process.

5. **Current Challenges and Future Directions**: Summarizes the main challenges faced in the development of ADCs and suggests some possible research directions to overcome these challenges and promote the further development of ADC technology.

Overall, this review article aims to provide comprehensive guidance for the research and production of ADCs, helping researchers and companies better understand and address the complexities and challenges in the ADC manufacturing process.